Jun 02, 2025
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sep 14, 2020
PANTHERx® Rare Pharmacy Selected by Blueprint Medicines to Distribute GAVRETO(TM) (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
Dec 10, 2019
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST
Nov 06, 2019
Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
Nov 05, 2019
Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results
Aug 13, 2019
CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study
Aug 07, 2019
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Aug 06, 2019
Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference
Aug 01, 2019
Blueprint Medicines Reports Second Quarter 2019 Financial Results
Jul 25, 2019
Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
Jul 09, 2019
CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST
Jun 15, 2019
Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress
Jun 14, 2019
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Jun 03, 2019
Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019
May 08, 2019
Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care Conference
May 02, 2019
Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
Apr 15, 2019
CStone received IND approval in China for avapritinib Phase I/II bridging registrational study in patients with advanced gastrointestinal stromal tumors
Apr 02, 2019
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
Mar 28, 2019
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
Mar 27, 2019
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock